Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated